Iliff L D, Du Boulay G H, Marshall J, Ross Russell R W, Symon L
Arzneimittelforschung. 1979;29(8a):1277-8.
Cerebral blood flow (CBF) was measured before and after i.v. injection of the cerebral vasodilator 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) in 13 patients with cerebrovascular disease. CBF increased in seven. The possibility is discussed that the effect of the drug in the other patients may have been masked by a fall of CBF which occurs during sequential measurement of patients at rest. Nicergoline is an alpha-adrenergic receptor blocking agent which affects cerebral blood flow by reducing cerebrovascular resistance. The present study was undertaken to assess the acute effect of the drug on cerebral blood flow and blood pressure in patients with cerebrovascular diseases.
对13例脑血管疾病患者静脉注射脑血管扩张剂10-甲氧基-1,6-二甲基-麦角灵-8β-甲醇-(5-溴烟酸酯)(尼麦角林，喜得镇)前后测量脑血流量(CBF)。7例患者的脑血流量增加。讨论了在静息状态下对患者进行连续测量时，其他患者中药物的作用可能被脑血流量下降所掩盖的可能性。尼麦角林是一种α-肾上腺素能受体阻滞剂，通过降低脑血管阻力来影响脑血流量。本研究旨在评估该药物对脑血管疾病患者脑血流量和血压的急性影响。
